N
Naurex
Biotech & Life Sciences · Evanston, United States · Founded 2008
Developing novel modulators of the NMDA receptor to treat challenging diseases of the brain and central nervous system MoreLess
Naurex, a subsidiary of AbbVie, operates in the biopharmaceutical sector, focusing on developing and delivering advanced therapies for complex medical conditions. The company primarily serves healthcare providers and patients, aiming to address unmet medical needs through innovative solutions. Naurex operates in a highly regulated market, adhering to stringent legal and clinical guidelines to ensure the safety and efficacy of its products. The business model revolves around extensive research and development (R&D), clinical trials, and strategic partnerships to bring new treatments to market. Revenue is generated through the sale of approved therapies, licensing agreements, and collaborations with other pharmaceutical entities. Naurex's core competencies include expertise in biologics, small molecules, and novel drug delivery systems, positioning it as a leader in the biopharmaceutical industry.
Keywords: biopharmaceutical, therapies, clinical trials, healthcare, R&D, biologics, small molecules, drug delivery, innovation, partnerships.
Company overview
Naurex company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2008
- Headquarters
- Evanston, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 77.2
Valuation & funding
Naurex funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jul 2015 | $560M | $560M | Allergan | — |
| SERIES COther financing | Dec 2014 | $80M | $320M | Cowen Group · Latterell Venture Partners · Takeda Ventures · Savitr Capital | — |
| SERIES COther financing | May 2014 | $25M | $100M | Takeda · Baxter International · Shire · Lundbeck | — |
| SERIES BOther financing | Dec 2012 | $38M | $152M | Latterell Venture Partners · Savitr Capital · Baxter International · Druid BioVentures | — |
| SERIES AOther financing | May 2011 | $18M | $72M | Adams Street Partners · Latterell Venture Partners · Takeda Ventures · Pathofinder | — |
| DEBTDebt | Feb 2011 | Takeda Ventures | — | ||
| SPINOUTOther financing | Jan 2008 | Northwestern University | — |
Growth signals
Naurex website traffic
Latest recorded traffic for Naurex is 16K monthly website visits. Naurex's team grew 57.1% over the past year.
Comparisons
Naurex compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Naurex's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Naurex has talent and traffic
team presence
In the news
Latest news about Naurex
Recent press, funding announcements, and product moves mentioning Naurex — open to read from the original sources.
Market sentiment
What the market is saying about Naurex
An AI-synthesized read of the highest-engagement posts about Naurex on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Naurex’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.